12:01 PM EST - Tekmira Pharmaceuticals Corp. : announced that its fiscal 2008 net loss was $14.3 million or $0.35 per common share, compared to a net loss of $2.6 million or $0.11 per common share in 2007. Revenue from research and development collaborations, licensing fees and milestone payments was $11.7 million in 2008 as compared to $15.8 million in 2007. Tekmira noted that it will continue to provide collaborative research services to Alnylam under a collaborative agreement until August 14, 2009 whereby Alnylam will fund a minimum of $2.0 million per annum for the provision of Tekmira research staff. Under a new Manufacturing Agreement, Tekmira will continue to be the exclusive manufacturer of any products required by Alnylam through to the end of phase 2 clinical trials that utilize Tekmira's intellectual property. Alnylam will pay for the provision of staff and for external costs incurred. Under the new Manufacturing Agreement there is a contractual minimum of $11.2 million in payments from Alnylam to Tekmira for the three years from 2009 to 2011 for the provision of staff. Tekmira Pharmaceuticals Corp.
shares T.TKM are trading down $0.05 at $0.58.
